Physics Bucharest 2017

Target volume adaptation in NSCLC

Overall goal: lower NTCP and higher TCP due to dose escalation

I Tumor regression 0.6%-2.4% per day, fast decrease in tumor volume is associated with worse outcome (non-adenocarcinoma patients) I Measurable tumor regression occurs in 40% of the patients (progression only in 1%), and is mostly visible in the fourth week of radio(chemo)therapy I Tumor volume decrease is larger in patients simultaneously treated with radiochemotherapy than in those treated sequentially (50.1% versus 33.7%, p =0.003) I Planning studies on possible dose escalation have reported different results

Sonke, Belderbos. Sem Radiat Oncol 2011; Brink, et al ., Radiother Oncol 2014; Zwienen, et al . Int J Radiat Oncol Biol Phys 2008; Berkovic, et al . Acta Oncol 2015